A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.
Also called NCT07724340
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- Antag Therapeutics
- Registry
-
NCT07724340
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07724340. Randomized; double masking; primary purpose treatment. Start 2026-06-19 (actual); primary completion 2027-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
- Condition
- Adults With Overweight/Obesity and Type 2 Diabetes
- Intervention (Drug)
- AT673 low dose
- Intervention (Drug)
- AT673 high dose
- Intervention (Drug)
- Placebo
- Lead sponsor
- Antag Therapeutics
Record details
- Record id
cardio:ct-nct07724340- Content hash
c3cba921307dbcb5dcf02a0e641bb3a7a345262c999ae8ca13dceecbdc0bcf90